Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2a Clinical Trial to Assess the Safety and Efficacy of C3 Inhibitor AMY-101, in Adults With Gingivitis

Next Previous
Trial Profile

A Phase 2a Clinical Trial to Assess the Safety and Efficacy of C3 Inhibitor AMY-101, in Adults With Gingivitis

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 27 Jan 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AMY 101 (Primary)
  • Indications Gingivitis; Periodontitis
  • Focus Therapeutic Use
  • Sponsors Amyndas Pharmaceuticals

Most Recent Events

  • 01 Dec 2021 Primary endpoint (Change in mean gingival index (MGI)) has been met as per results published in the Journal of Clinical Investigation
  • 01 Dec 2021 Results published in the Journal of Clinical Investigation
  • 19 Mar 2021 According to an Amyndas Pharmaceuticals media release, company is planning to discussing these results with the U.S. FDA and other regulatory agencies, to design the best path forward, ideally through a multi-center phase 3 trial of AMY-101.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top